Maze (MAZE) CMO Harold Bernstein Exercises Options, Sells Shares

What Happened
Harold Bernstein, President R&D and Chief Medical Officer of Maze Therapeutics (MAZE), exercised equity awards and sold stock on September 1, 2026. He exercised 16,141 option shares at $10.42 per share (cost $168,189) and immediately sold those 16,141 shares in the open market at a weighted-average price of $26.36 per share for aggregate proceeds of $425,512. The filing also reports the acquisition (and related dispositions at $0) of 20,000 shares tied to a separate award/vesting event on the same date (see footnotes on RSUs/vesting).

Key Details

• Transaction date: September 1, 2026. Form 4 filed September 3, 2026 (filed within the normal reporting window).
• Sale: 16,141 shares sold in multiple trades at a weighted-average price of $26.36 (range $26.11–$26.64); total sale proceeds reported $425,512.
• Exercise: 16,141 shares exercised at $10.42 per share; total exercise cost $168,189.
• Additional reported activity: 20,000 shares reported as acquired at $0.00 and related derivative disposals at $0.00 (per footnotes, these reflect award/vesting/settlement mechanics—see F4–F6).
• Shares owned after transaction: Not specified in this filing.
• Notable footnotes: F1 = sale effected under a Rule 10b5-1 trading plan; F2 = weighted-average sale price and price range; F3–F6 = vesting schedule and RSU definitions/terms indicating part of the activity relates to vesting awards.
• Transaction codes: M = exercise/conversion of derivative; S = open-market sale.

Context
This sequence (exercise of options followed by immediate sale of the same shares) is commonly a cashless or monetization event — the insider realized proceeds while the sale was executed under a pre-established 10b5-1 plan, which helps avoid timing concerns. The filing also shows award/vesting activity (RSUs or similar) on the same date; some reported $0 disposals likely reflect settlement/withholding mechanics rather than open-market sales. The filing is factual and timely; it does not state the insider’s remaining ownership or the tax/treatment details beyond the footnotes.